FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3097014789> ?p ?o ?g. }

• W3097014789 endingPage "18" @default.
• W3097014789 startingPage "16" @default.
• W3097014789 abstract "Background: Acalabrutinib (A) is a next-generation, highly selective, covalent Bruton tyrosine kinase (BTK) inhibitor approved for marketing by the US FDA in patients (pts) with chronic lymphocytic leukemia (CLL). While responses to A monotherapy are durable in CLL, response depth may be enhanced with combination therapy and potentially allow treatment discontinuation. The safety and efficacy of A plus a CD20 antibody (obinutuzumab [O] or rituximab [R]) and the BCL-2 inhibitor venetoclax (V) were examined in a phase 1b study (CL-003; NCT02296918) in relapsed/refractory (R/R) or treatment-naïve (TN) CLL pts. Methods: Pts were aged ≥18 years with intermediate or high-risk CLL (R/R or TN) and an Eastern Cooperative Oncology Group performance status (ECOG PS) ≤2. Prior BTK inhibitor treatment was allowed for R/R pts if discontinuation was not due to CLL progression. R/R CLL pts received oral (PO) A 100 mg twice daily (BID) until progression, plus intravenous (IV) R 375 mg/m2 for 9 infusions (cycles 2-7), plus V PO daily per standard dosing (cycles 3-15). TN CLL pts received PO A and V (as above) plus IV O per standard dosing (cycles 2-7). The primary endpoint was safety. Secondary endpoints included investigator-assessed overall response rate (ORR, partial response [PR] or better) at cycle 16, complete response (CR) rate, undetectable minimal residual disease (uMRD) rate, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and pharmacokinetics (PK). Results: Twelve pts were included in each cohort (R/R: male, n=9 [75%], median [range] age: 66 [55-72] y; TN: male, n=9 [75%], median [range] age: 61 [42-73] y). All pts had ECOG PS ≤1; 6/8 (75%) R/R and 8/10 (80%) TN pts had unmutated IGHV (&lt;2% variance from germline sequence). The median number of prior therapies in R/R pts was 1 (range, 1-3). At a median follow-up of 23.2 mo (range: 19.8-25.3) in R/R pts and 22.0 mo (range: 19.5-24.4) in TN pts, 11 (92%) and 10 (83%) pts remained on treatment, respectively. Reasons for treatment discontinuation were adverse events (AEs) in 1 pt (8%) in each cohort (R/R: grade 1 purpura; TN: grade 2 head discomfort), and withdrawal by 1 pt (8%) in the TN cohort. The median number of treatment cycles in R/R pts was 23 (range: 14.9-27.5) for A, 6 (6-6) for R, and 13 (10.0-13.7) for V, and in TN pts was 23 (18.0-24.8) for A, 6 (6-6) for O, and 13 (13.0-13.5) for V. Reported AEs were similar to the individual agents' toxicity profiles (Table 1). Among AEs of interest, 7 R/R pts (58%) and 4 TN pts (33%) had cardiac AEs; grade ≥3 cardiac AEs were reported in 1 pt (8%). Atrial fibrillation was reported in 1 pt (grade 3; R/R pt with prior atrial fibrillation history). No ventricular arrhythmias were reported. Three R/R pts (25%) and 7 TN pts (58%) had hypertension AEs; none were grade ≥3. The most frequent infections (≥40%) were upper respiratory tract infection (URTI; 50%) in R/R pts and URTI (67%), sinusitis (42%), and nasopharyngitis (42%) in TN pts. Grade ≥3 infections occurred in 3 TN pts (lung infection, n=2 [17%]; prostate infection, staphylococcal bacteremia, staphylococcal sepsis, n=1 [8%] each) and no R/R pts. Six R/R pts (50%) and 3 TN pts (25%) had infusion-related reactions; none were grade ≥3. One R/R pt (8%) and 6 TN pts (50%) had decreased neutrophil counts; all were grade ≥3. No tumor lysis syndrome AEs, Richter transformations, or deaths were reported. After 16 cycles, ORR was 92% (95% CI: 62-100) in R/R pts and 100% (95% CI: 74-100) in TN pts. At the time of data cutoff, 50% of pts in each cohort had achieved CR or CR with incomplete marrow recovery (CRi). All pts with CR or CRi achieved uMRD (10-4) in peripheral blood (PB) at the time of CR/CRi or earlier. Overall, 8 (67%) R/R and 9 (75%) TN pts achieved uMRD (10-4) in PB at cycle 10 (Table 2). Median DOR, PFS, and OS were not reached in either group. Estimated 18-mo PFS and OS rates were 100% (95% CI: not estimable) in both cohorts. The PK of A and its active metabolite, ACP-5862, were consistent when given as monotherapy or with V, R, or O. The PK of V remained within the range observed with monotherapy (Salem et al. J Clin Pharmacol. 2017;57:484-492) when given with A. Conclusions: Combination therapy with A plus an anti-CD20 antibody and BCL-2 inhibitor leads to a tolerable safety profile with high CR and uMRD rates in both R/R and TN CLL pts, with minimal to no drug-drug interactions. Disclosures Woyach: Pharmacyclics, Janssen, Morphosys, Karyopharm, Verastem, Abbvie, Lox: Research Funding; Pharmacyclics LLC, an AbbVie Company, AbbVie, Janssen, AstraZeneca, ArQule: Honoraria; Janssen, Pharmacyclics, AstraZeneca, Abbvie, Arqule: Consultancy. Blachly:AbbVie, AstraZeneca, KITE Pharma: Consultancy. Rogers:Janssen: Research Funding; AstraZeneca: Consultancy, Other: Travel Funding; Pharmacyclics: Consultancy; AbbVie: Consultancy, Research Funding; Genentech: Research Funding; Acerta Pharma: Consultancy. Lozanski:Genentech, Novartis, Beckman Coulter: Research Funding. Andersen:Ohio State University: Current Employment, Research Funding. Patel:AstraZeneca: Current Employment, Current equity holder in publicly-traded company. Munugalavadla:Acerta Pharma/AstraZeneca: Current Employment, Current equity holder in publicly-traded company; Gilead Sciences: Current equity holder in publicly-traded company, Other: Family Association. Butturini:Puma Biotechnology: Divested equity in a private or publicly-traded company in the past 24 months; Dynavax, Puma Biotechnology: Ended employment in the past 24 months; Roche/Genentech, Pfeizer, AstraZeneca, Amgen: Current equity holder in publicly-traded company; Acerta Pharma: Current Employment. Xu:Acerta Pharma: Current Employment, Research Funding; AstraZeneca: Research Funding. Wang:Acerta Pharma: Current Employment. Byrd:Acerta Pharma: Research Funding; Syndax: Research Funding; Novartis: Research Funding; Kartos Therapeutics: Research Funding; Trillium: Research Funding; Leukemia and Lymphoma Society: Other; Janssen: Consultancy; Pharmacyclics LLC, an AbbVie Company, Gilead, TG Therapeutics, BeiGene: Research Funding; Pharmacyclics LLC, an AbbVie Company, Gilead, TG Therapeutics, Novartis, Janssen: Speakers Bureau; Pharmacyclics LLC, an AbbVie Company, Janssen, Novartis, Gilead, TG Therapeutics: Other; Vincera: Research Funding." @default.
• W3097014789 created "2020-11-09" @default.
• W3097014789 creator A5000921376 @default.
• W3097014789 creator A5003588752 @default.
• W3097014789 creator A5011640513 @default.
• W3097014789 creator A5014241029 @default.
• W3097014789 creator A5018821266 @default.
• W3097014789 creator A5026365161 @default.
• W3097014789 creator A5037098355 @default.
• W3097014789 creator A5042260558 @default.
• W3097014789 creator A5050633601 @default.
• W3097014789 creator A5050724356 @default.
• W3097014789 creator A5051619378 @default.
• W3097014789 creator A5069318162 @default.
• W3097014789 creator A5071804123 @default.
• W3097014789 creator A5072098360 @default.
• W3097014789 creator A5080781659 @default.
• W3097014789 creator A5087424125 @default.
• W3097014789 date "2020-11-05" @default.
• W3097014789 modified "2023-09-30" @default.
• W3097014789 title "Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia" @default.
• W3097014789 doi "https://doi.org/10.1182/blood-2020-136317" @default.
• W3097014789 hasPublicationYear "2020" @default.
• W3097014789 type Work @default.
• W3097014789 sameAs 3097014789 @default.
• W3097014789 citedByCount "10" @default.
• W3097014789 countsByYear W30970147892021 @default.
• W3097014789 countsByYear W30970147892022 @default.
• W3097014789 crossrefType "journal-article" @default.
• W3097014789 hasAuthorship W3097014789A5000921376 @default.
• W3097014789 hasAuthorship W3097014789A5003588752 @default.
• W3097014789 hasAuthorship W3097014789A5011640513 @default.
• W3097014789 hasAuthorship W3097014789A5014241029 @default.
• W3097014789 hasAuthorship W3097014789A5018821266 @default.
• W3097014789 hasAuthorship W3097014789A5026365161 @default.
• W3097014789 hasAuthorship W3097014789A5037098355 @default.
• W3097014789 hasAuthorship W3097014789A5042260558 @default.
• W3097014789 hasAuthorship W3097014789A5050633601 @default.
• W3097014789 hasAuthorship W3097014789A5050724356 @default.
• W3097014789 hasAuthorship W3097014789A5051619378 @default.
• W3097014789 hasAuthorship W3097014789A5069318162 @default.
• W3097014789 hasAuthorship W3097014789A5071804123 @default.
• W3097014789 hasAuthorship W3097014789A5072098360 @default.
• W3097014789 hasAuthorship W3097014789A5080781659 @default.
• W3097014789 hasAuthorship W3097014789A5087424125 @default.
• W3097014789 hasBestOaLocation W30970147891 @default.
• W3097014789 hasConcept C121332964 @default.
• W3097014789 hasConcept C126322002 @default.
• W3097014789 hasConcept C142424586 @default.
• W3097014789 hasConcept C143998085 @default.
• W3097014789 hasConcept C197934379 @default.
• W3097014789 hasConcept C203092338 @default.
• W3097014789 hasConcept C2776694085 @default.
• W3097014789 hasConcept C2777063308 @default.
• W3097014789 hasConcept C2777607594 @default.
• W3097014789 hasConcept C2777938653 @default.
• W3097014789 hasConcept C2778375690 @default.
• W3097014789 hasConcept C2778461978 @default.
• W3097014789 hasConcept C2778715236 @default.
• W3097014789 hasConcept C2778822529 @default.
• W3097014789 hasConcept C2779338263 @default.
• W3097014789 hasConcept C2779675984 @default.
• W3097014789 hasConcept C2779788671 @default.
• W3097014789 hasConcept C2779878957 @default.
• W3097014789 hasConcept C2780653079 @default.
• W3097014789 hasConcept C535046627 @default.
• W3097014789 hasConcept C71924100 @default.
• W3097014789 hasConcept C87355193 @default.
• W3097014789 hasConcept C90924648 @default.
• W3097014789 hasConceptScore W3097014789C121332964 @default.
• W3097014789 hasConceptScore W3097014789C126322002 @default.
• W3097014789 hasConceptScore W3097014789C142424586 @default.
• W3097014789 hasConceptScore W3097014789C143998085 @default.
• W3097014789 hasConceptScore W3097014789C197934379 @default.
• W3097014789 hasConceptScore W3097014789C203092338 @default.
• W3097014789 hasConceptScore W3097014789C2776694085 @default.
• W3097014789 hasConceptScore W3097014789C2777063308 @default.
• W3097014789 hasConceptScore W3097014789C2777607594 @default.
• W3097014789 hasConceptScore W3097014789C2777938653 @default.
• W3097014789 hasConceptScore W3097014789C2778375690 @default.
• W3097014789 hasConceptScore W3097014789C2778461978 @default.
• W3097014789 hasConceptScore W3097014789C2778715236 @default.
• W3097014789 hasConceptScore W3097014789C2778822529 @default.
• W3097014789 hasConceptScore W3097014789C2779338263 @default.
• W3097014789 hasConceptScore W3097014789C2779675984 @default.
• W3097014789 hasConceptScore W3097014789C2779788671 @default.
• W3097014789 hasConceptScore W3097014789C2779878957 @default.
• W3097014789 hasConceptScore W3097014789C2780653079 @default.
• W3097014789 hasConceptScore W3097014789C535046627 @default.
• W3097014789 hasConceptScore W3097014789C71924100 @default.
• W3097014789 hasConceptScore W3097014789C87355193 @default.
• W3097014789 hasConceptScore W3097014789C90924648 @default.
• W3097014789 hasIssue "Supplement 1" @default.
• W3097014789 hasLocation W30970147891 @default.
• W3097014789 hasOpenAccess W3097014789 @default.
• W3097014789 hasPrimaryLocation W30970147891 @default.
• W3097014789 hasRelatedWork W1550739321 @default.
• W3097014789 hasRelatedWork W2106082064 @default.

• next